Engineered immune cells take on lupus and scleroderma

NCT ID NCT06347718

Recruiting now Disease control Sponsor: Miltenyi Biomedicine GmbH Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tests a one-time treatment using a patient's own immune cells, engineered to target and destroy B cells, which drive autoimmune diseases like lupus, scleroderma, and myositis. 24 adults with active disease will receive the therapy after a short chemotherapy. The main goal is to check safety, but researchers will also look for signs of disease improvement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anti-CD19 CAR T cell therapy
What this could lead to: If successful, this could offer a new treatment option for severe autoimmune diseases like lupus and scleroderma, potentially reducing symptoms and disease activity.
What could go wrong: This is an early phase 1/2 trial with only 24 participants, so results may not apply to everyone. Risks include cytokine release syndrome and nerve toxicity, and long-term effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dermatomyositis polymyositis systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DERMATOMYOSITIS POLYMYOSITIS SYSTEMIC LUPUS ERYTHEMATOSUS SYSTEMIC SCLEROSIS

Contacts and locations

Locations

Universitätsklinikum Erlangen
RECRUITING

Erlangen, Bavaria, 91054, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.